Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX17725 in Healthy Participants and Netherton Syndrome
NCT06539507Phase 1Recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Sep 2024
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of BCX17725 in Netherton syndrome (NS) (6 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Incidence of treatment-emergent adverse events at Day 106 and Change from baseline in Ichthyosis Area and Severity Index score at Week 12. Started Sep 2024; status: recruiting.
02
Drugs
BCX17725
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT06539507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539507.